GLP-1s: Overdosing, Side Effects & Long-Term Risks | Dr. Abud Bakri & Dr. Andrew Huberman
Guest appearances — Dr. Abud Bakri — GLP-1s: Overdosing, Side Effects & Long-Term Risks | Dr. Abud Bakri & Dr. Andrew Huberman
Channel: Huberman Lab Clips · Our label: Guest appearance — Dr. Abud Bakri as guest on host channels. The host channel is named on every page. · Source: youtube.com/watch?v=-1gOQt2swYM
Guest appearance: Dr. Abud Bakri appears as a guest on Huberman Lab Clips. This page is filed under the host channel and tagged as a guest appearance in our library.
What this video covers
Makes sense, » you know, depending on which pathways are being affected. Is that something that people need to be concerned about? Do you think people can micro dose this stuff? Because a lot of people are micro doing it regardless of what their source is.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- They’re taking a lot less than the kind of standard clinical trials would be.
I’ll tell you that you have your you know semiglutide which is obey and vigov is the FDA approved version for the weight loss.
- Zepbound being the FDA approved version for weight loss that allows them to keep their patents for longer.
- Before it wasn’t FDA approved for weight loss.
- So the question because what happens is people go to these websites, they they buy one more peptide and they got a great result and they’ll be like, you know, let me add three more peptides on peptides.
- There there is no pre GLP1 world for us as clinicians, as health enthusiasts.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.